Orphan drugs are used to diagnose, prevent, and treat rare medical disorders. These drugs aim to meet particular public health requirements and generally have a limited production, only for a small group of patients. Orphan drugs help in treating several oncological, metabolic, hematologic, immunologic, infectious, and neurological ailments. These ailments majorly include lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, etc.
Request for a free sample copy of this report: https://www.imarcgroup.com/orphan-drugs-market/requestsample
The high prevalence of cancer and other rare genetic disorders is primarily driving the need for orphan drugs. Several pharma companies are focusing on developing new orphan drugs for providing personalized therapies for patients. Additionally, the higher approval rate of several pipeline drugs, along with the introduction of numerous favorable government policies to curb the spread of various infectious diseases, is also catalyzing the market growth. Moreover, extensive R&D activities for the development of biological orphan drugs that can treat cancer and minimize the damage caused to the stem cells are further expected to drive the market for orphan drugs in the coming years.
Orphan Drugs Market 2020-2025 Analysis and Segmentation:
The report has segmented the market on the basis of drug type, disease type, phase, top selling drug, distribution channel and region.
Breakup by Drug Type:
Breakup by Disease Type:
Breakup by Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
Breakup by Top Selling Drugs:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
Explore full report with table of contents: https://www.imarcgroup.com/orphan-drugs-market
Breakup by Region:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- AbbVie Inc.(NYSE: ABBV)
- Alexion Pharmaceuticals Inc. (NASDAQ: ALXN)
- Amgen Inc. (NASDAQ: AMGN)
- Biogen Inc. (NASDAQ: BIIB)
- Bristol-Myers Squibb Company
- Hoffmann-La Roche AG (Roche Holding AG)
- Jazz Pharmaceuticals Plc (NASDAQ: JAZZ)
- Johnson & Johnson (NYSE: JNJ)
- Merck & Co. Inc. (NYSE: MRK)
- Novartis AG (NYSE: MRK)
- Pfizer Inc. (NYSE: PFE)
- Sanofi S.A. (EPA: SAN)
- Takeda Pharmaceutical Company Limited (TYO: 4502)
- Teva Pharmaceutical Industries Ltd. (TLV: TEVA)
Key highlights of the report:
- Market Performance (2014-2019)
- Market Outlook (2020- 2025)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Browse Related Report:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1 6317911145
Address:30 N Gould St, Ste R
State: WY 82801
Country: United States